Company Overview of Aptalis Holdings Inc.
Aptalis Holdings Inc. develops, manufactures, licenses, and markets therapies for cystic fibrosis (CF) and gastrointestinal disorders. Its principal products include ZENPEP and ULTRESA for the treatment of exocrine pancreatic insufficiency (EPI) due to CF or other conditions; VIOKACE for the treatment of EPI due to chronic pancreatitis or pancreatectomy in adults; PANZYTRAT for the treatment of EPI and pancreatic enzyme deficiency; and RECTIV for the treatment of moderate to severe pain associated with chronic anal fissure. The company’s products also comprise CARAFATE for the short-term treatment of active duodenal ulcers; PYLERA for the treatment of patients with helicobacter pylori, infec...
100 Somerset Corporate Boulevard
Bridgewater, NJ 08807
Founded in 2008
Key Executives for Aptalis Holdings Inc.
President of Aptalis Pharma
Senior Vice President, General Counsel and Corporate Secretary
Chief Human Resources Officer and Senior Vice President
Chief Research Officer and Senior Vice President
Compensation as of Fiscal Year 2014.
Aptalis Holdings Inc. Key Developments
Aptalis Holdings Inc. Presents at BIO International Convention, Jun-25-2014 11:00 AM
Jun 17 14
Aptalis Holdings Inc. Presents at BIO International Convention, Jun-25-2014 11:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.
Forest Laboratories To Reportedly Acquire Aptalis From TPG Capital
Jan 7 14
Forest Laboratories Inc. (NYSE:FRX) is nearing an agreement to acquire Aptalis Holdings Inc. from TPG Capital, L.P. for about $3 billion, a person familiar with the matter said. A deal announcement could come as early as January 8, 2014, the person said, cautioning that negotiations were still being finalized. The source asked not to be identified because the talks are confidential. According to Reuters, Forest and Aptalis did not immediately respond to requests for comment. TPG declined to comment.
Aptalis Holdings Seeks Acquisitions
Dec 26 13
Aptalis Holdings Inc. has made an offering of $500 million. A part of the proceeds will be used for future acquisitions.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries